Exhibit 99.1
                                                                    ------------

PROVECTUS
PHARMACEUTICALS, INC.

Provectus Pharmaceuticals Receives $1 Million in Financing

KNOXVILLE, Tenn, June 28, 2004 -- Provectus Pharmaceuticals,  Inc. (OTCBB: PVCT)
announces  that it has completed a  fixed-price  financing of $1 million for the
purchase of restricted common shares. The total financing to the company will be
$2.3 million if all warrants are  exercised.  The  financing was obtained from a
group of accredited investors.

"With part of these funds, a  variable-price  debenture will be retired,  and we
will withdraw the  registration  of 2.4 million  shares that was required by the
debenture.  These shares will not enter the tradable  float,  which is currently
approximately 3 million shares," said Provectus CEO Craig Dees, Ph.D. "Remaining
funds will be used to advance sales of our  over-the-counter  (OTC) products and
advance the  development of our oncology drug,  ProvectaTM.  We anticipate  that
human clinical trials for cancer patients using  ProvectaTM could begin as early
as fall of this year."

Provectus  Pharmaceuticals  Inc. licenses and sells products in three sectors of
the health-care industry: 1) prescription medications and treatments, 2) medical
devices,  and  3)  over-the-counter  (OTC)  pharmaceuticals.  Prescription  drug
products and devices address several forms of difficult-to-treat cancers as well
as diseases of the skin. OTC products address complementary  markets,  primarily
those involving skin care and comfort.

The  company's  offices and  laboratory  are located at 7327 Oak Ridge  Highway,
Suite A Knoxville,  TN 37931;  telephone:  865/769-4011.  For more  information,
contact  the  company  at   info@pvct.com  or  visit  the  corporate  Web  site:
www.pvct.com.

Forward-Looking  Statements
This  release  and  others  statements  issued  or made from time to time by the
company  or  its   representatives   contain   statements  that  may  constitute
forward-looking  statements.  Those statements include statements  regarding the
intent,  belief or  current  expectations  of the  company  and  members  of its
management  teams as well as the  assumptions on which the statements are based.
Prospective investors are cautioned that such forward-looking statements are not
guarantees of future performance and involve risks and  uncertainties,  and that
actual  results  may  differ   materially   from  those   contemplated  by  such
forward-looking  statements.
- ----------------

Corporate  Contact:  Provectus  Pharmaceuticals,  Craig Dees, CEO (865) 769-4011
Media   Contacts:   Hilary   Kaye   Associates,   Hilary  Kaye  or  Eve  Gumpel,
egumpel@hkamarcom.com (714) 426-0444 (PDT)
- ---------------------

Source: Provectus Pharmaceuticals Inc.